Zoetis Inc. $ZTS Position Lessened by Huntington National Bank

Posted by Donald Scott on May 29th, 2026

Huntington National Bank trimmed its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 27.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,206 shares of the company’s stock after selling 14,425 shares during the period. Huntington National Bank’s holdings in Zoetis were worth $4,681,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of ZTS. Brighton Jones LLC raised its holdings in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares in the last quarter. Intech Investment Management LLC raised its holdings in shares of Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after acquiring an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after acquiring an additional 1,422 shares in the last quarter. Finally, Glenview Trust co raised its holdings in shares of Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after acquiring an additional 506 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

NYSE ZTS opened at $78.36 on Friday. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $172.23. The stock’s 50-day moving average is $105.08 and its two-hundred day moving average is $117.31. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The firm has a market cap of $32.85 billion, a P/E ratio of 12.99, a price-to-earnings-growth ratio of 1.30 and a beta of 0.87.

Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same quarter last year, the business earned $1.48 EPS. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

Positive Sentiment: Zoetis presented at the Stifel Jaws & Paws Conference, which may help reassure investors by giving management a venue to discuss strategy, operations, and the path forward. Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Neutral Sentiment: Argus reiterated a “hold” rating on Zoetis, suggesting analysts are not currently seeing a major catalyst for a near-term rebound. Zoetis had its “hold” rating reaffirmed by Argus
Negative Sentiment: Multiple law firms announced or expanded class action efforts against Zoetis, with investors alleging harm tied to the period from January 14, 2025 through May 6, 2026; these repeated filings keep legal overhang front and center for shareholders. Rosen Law Firm Urges Zoetis Inc. (NYSE: ZTS) Stockholders to Contact the Firm for Information About Their Rights
Negative Sentiment: The lawsuits stem from Zoetis’ Q1 results, when the company missed earnings and revenue estimates and cut full-year guidance, raising concerns about growth and execution. Zoetis (ZTS) Securities Fraud Investigation – Levi & Korsinsky

Wall Street Analysts Forecast Growth

ZTS has been the subject of several recent research reports. Bank of America increased their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. BTIG Research reiterated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Finally, Stifel Nicolaus cut their price objective on Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a report on Friday, May 22nd. Six investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $133.92.

Check Out Our Latest Stock Report on Zoetis

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Michael B. Mccallister acquired 3,000 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the purchase, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Frank A. Damelio acquired 6,650 shares of the company’s stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 11,650 shares of company stock worth $886,384 over the last 90 days. Insiders own 0.22% of the company’s stock.

Zoetis Profile

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.